NTRA - Natera gets MRD testing contract from US Dept of Veterans Affairs

• Natera ( NASDAQ: NTRA ) said Wednesday it was awarded a nationwide contract by the U.S. Dept. of Veterans Affairs National Precision Oncology Program, effective Sept. 15.
• The contract is for minimal residual disease and monitoring services with Natera's ( NTRA ) personalized and tumor-informed MRD test Signatera.
• Signatera is a circulating tumor DNA test for MRD assessment in patients previously diagnosed with cancer. The test has been granted three breakthrough device designations by the FDA.

For further details see: